November 8, 2022
OncoBone has received funding from Centre for Economic Development, Transport and the Environment (ELY Centre) for developing a Virtual CRO concept as a new business model. The project is co-funded by European Regional Development Fund of the European Union.
Jussi Halleen, CEO of OncoBone says: “We thank ELY Centre and European Union for the support that will be extremely important for our business development. We are excited to develop our Virtual CRO concept to better meet requirements of our clients.”
August 23, 2022
OncoBone is excited to announce publication of a book ‘Animal Models for the Development of Cancer Immunotherapy’ by John Wiley & Sons, Inc in August 2022. OncoBone contributed to the book a chapter titled ‘Preclinical Osteoimmuno-Oncology Models to Study Effects of Immunotherapies on Bone Metastasis’. You can find a link to the book with additional details from the following link.
Tiina Kähkönen, CSO of OncoBone comments: “We would like to thank Seng-Lai Tan for inviting us to participate in writing a chapter in this book. It was a great honor to be involved together with leading experts in the field. We hope that our chapter on bone metastasis with information on animal models, technical details and used technologies and analyses will encourage researchers to use these models especially when testing effects on immunotherapies on cancers that metastasize to the skeleton”.
Contact us at firstname.lastname@example.org to learn more.
April 8, 2022
OncoBone is excited to announce partnership with the health tech start-up company Aurora Health Sciences. Aurora’s mission is to promote human health by providing technological innovations to consumers for better monitoring, understanding and maintaining their health. The role of OncoBone in the partnership is to provide scientific expertise to projects aiming at developing Aurora’s innovations further, generating and securing new IP, and assisting in commercialization of the products. New releases on advancements will be announced later during the year.
Teemu Penttilä, CEO of Aurora Health Sciences says: “During the past 6 months we have already established a good working relationship with OncoBone, and we are happy to welcome them as scientific advisors in Aurora Health Sciences. We are confident that through their scientific expertise OncoBone can give strong support for our novel technological innovations to become a global breakthrough in supporting human health.”
Tiina Kähkönen, CSO of OncoBone comments: “Supporting and maintaining health is close to our hearts in OncoBone. Being asked to be involved in a company devoted for achieving this goal through novel technological innovations and natural products is a great honour for us. We strongly believe that together with Aurora Health Sciences we can have a global impact on improving human health.”
Contact us at email@example.com to learn more.
November 23, 2021
OncoBone is pleased to announce signing a distributor agreement with a OsteoSys, a Korean-based company specialized in products for monitoring bone health in humans and animals. The distributor agreement covers Europe, with focus in Finland and Scandinavia.
Under the agreement, OncoBone will distribute iNSiGHT Dual-energy X-ray Absorptiometry (DXA), an easy-to-use, fast and non-invasive device for analyzing bone mineral density (BMD) and body composition in small animals in preclinical research.
Monet Hyungmin Lee, Sales Manager of OsteoSys says: “On behalf of OsteoSys, I am very pleased to announce a distributor agreement with OncoBone as our strategic business partner to officially distribute iNSiGHT, microDXA system, in Finland and Scandinavia. We are confident that OncoBone representatives as the authorized distributor of iNSiGHT can provide the very best service to our customers to aid research activities and to improve performance in the field of preclinical research.”
Tiina Kähkönen, CSO of OncoBone comments: “We are excited about the collaboration with OsteoSys. With a strong experience in using X-ray and DXA devices before, we are happy to acknowledge iNSiGHT as in our opinion the best DXA device for accurate and reliable measurement of BMD and body composition in small animals for scientists working in bone and metabolic disease fields.”
Contact us at firstname.lastname@example.org to learn more.
November 10, 2021
OncoBone representatives have over 20 years of experience working in CRO business and are globally well networked with many CRO companies. OncoBone has assisted and continues to assist pharma and biotech companied by making referrals to our partner CROs and identifying new CRO partners through our CRO evaluation service, especially in our key fields of expertise oncology, immuno-oncology and bone diseases.
Based on valuable feedback obtained from our clients and after successful completion of multiple projects, OncoBone is happy to launch a new full-service ‘Virtual CRO’ concept.
Jussi Halleen, CEO of OncoBone says: “As a Virtual CRO, OncoBone works as a traditional CRO taking care of all duties associated with the CRO and being fully responsible for the studies to the client. The difference is that the work is outsourced to CROs carefully selected together with the client.”
Tiina Kähkönen, CSO of OncoBone adds: “The Virtual CRO concept allows us to better serve our clients by selecting best possible partners to carry out the work for their research projects. As a Virtual CRO, we are happy to take responsibility in planning and monitoring the studies together with the client and assisting in interpretation of the obtained results.”
August 19, 2021
OncoBone is excited to announce partnership with the VYANTbio company vivoPharm, a preclinical CRO that provides proprietary oncology and immuno-oncology services, toxicology testing and bioanalytical analysis to the biotechnology and pharmaceutical industries.
The goal of the partnership includes OncoBone to expand visibility and client-base of vivoPharm especially in bone metastasis models, the core expertise area of OncoBone. The partnership also includes OncoBone to help vivoPharm in the development and marketing of additional new bone metastasis models.
Tiina Kähkönen, CSO of OncoBone says: “We are very excited to work with vivoPharm. A member of vivoPharm was involved in research that resulted in developing intratibial injection, the core technique used in many bone metastasis models. We are delighted to work with a true global leader who shares our passion to advance preclinical testing of therapies for bone metastatic disease.”
Melanie Keller, vivoPharm’s Division Head in Europe adds: “We are impressed about the scientific expertise of OncoBone in bone metastasis models. This together with their strong expertise in marketing and sales activities of bone metastasis models makes OncoBone a perfect partner for vivoPharm in order to expand visibility of both companies.”
July 21, 2021
OncoBone has partnered with Cellbox Solutions, a company focusing on innovative logistic solutions for the biomedical industry. Cellbox provides a new generation of portable incubators and compatible packaging solutions for live cell transport under laboratory conditions.
The portable incubators provide a time-efficient live cell transporting solution where no cryopreservation is needed, and the cells can be used right after arrival. Applications for the portable incubators include for example cell therapies, 3D cell cultures and organoids, organ-on-chips and microfluidic systems, and cell and biobank materials.
The goal of the partnership includes OncoBone to expand visibility and client-base of Cellbox Solutions. OncoBone will represent Cellbox Solutions in discussions with existing contacts of OncoBone, and find new potential clients by representing Cellbox Solutions in various mutually agreed scientific and partnering events.
May 31, 2021
OncoBone is pleased to announce partnering with BiomimX®, a technology-driven company developing innovative pre-clinical solutions based in Milan, Italy. The partnering includes OncoBone to provide its expertise to support BiomimX in expanding its visibility and client-base for its specialized screening services building upon uKnee, a model of pathological human joint on chip.
BiomimX is a pioneer in the development of functional predictive models of human organs and pathologies that will improve the way to test drugs and medical devices. Integrating 3D cell culture and mechanical stimulation, BiomimX offers the next generation organ-on-chip technology, allowing to recapitulate the physiological or pathological states of human organs with accurate precision. BiomimX’s portfolio includes uKnee, the first 3D in vitro pathological model of human Osteoarthritic (OA) joint to profile safety and efficacy of pharmaceutical products and intra-articular medical devices.
As part of the partnership OncoBone will represent BiomimX in the forthcoming events BIO Digital on June 14 – 18, 2021 and American Society for Bone and Mineral Research (ASBMR) Annual meeting on October 1 – 4, 2021.
March 2, 2021
OncoBone has entered into an agency agreement with Guangdong Gucon Biotech Co. Ltd (“Gucon”). The agreement is exclusive, including Gucon to help OncoBone in finding new business in China.
Jussi Halleen, CEO of OncoBone comments: “I have known Gucon for more than 10 years and I am convinced that through their expertise and large network of potential customers of OncoBone, Gucon will be able to contribute extensively in expanding our business in China.”
Simon Guo, General Manager of Gucon adds: “Gucon is excited to work with OncoBone and has strong expectations for the collaboration. Gucon expects that especially the strong scientific expertise of OncoBone in oncology and bone biology will be attractive to our network”
February 25, 2021
OncoBone is pleased to announce co-operation with the Shanghai-based preclinical CRO PharmaLegacy. In the co-operation OncoBone will provide its expertise to support PharmaLegacy in expanding its client-base especially in Europe.
Jussi Halleen, CEO of OncoBone says: “I know PharmaLegacy from 10 years back when I visited them in Shanghai. I was impressed then and am even more impressed today about their continuing success in preclinical CRO business. I am convinced that OncoBone is in an excellent position to help PharmaLegacy expanding their business further, especially in our key expertise fields oncology and bone diseases.”
Michael Zhang, VP of PharmaLegacy adds: “We are very impressed about the high reputation of OncoBone representatives in the fields of oncology and bone diseases. PharmaLegacy has high expectations for OncoBone for successful promotion of especially our oncology and non-human primate models in European markets.”
February 19, 2021
OncoBone is proud to announce joining Biocom as a member company. Biocom is the largest and most experienced life science association in California.
On February 23 – 25, 2021, OncoBone will attend Biocom Global Life Science Partnering Conference, an annual bio-pharma partnering conference that brings together leading deal makers and emerging biotechs from around the world.
On March 30, OncoBone will arrange a Biocom webinar “Working with CROs – From selection to managing relationships”, where Dr. Tiina Kähkönen, CSO of OncoBone will speak about “How to choose the right CRO”.
January 20, 2021
OncoBone and MediSapiens are pleased to announce their cooperation in promoting the newly released MediSapiens Genomics Software Suite (GSS).
GSS is a high-performance, cloud-based genomics back-end solution enabling genomic and clinical data integration and analytics. OncoBone will provide its expertise and extensive life science industry network to support MediSapiens in expanding its client-base for GSS.
Jussi Halleen, CEO of OncoBone comments: “The Genomics Software Suite has great potential for global success and we are delighted to have this opportunity to work with MediSapiens in this exciting project.”
Nils Effertz, CEO of MediSapiens adds: “We are pleased that OncoBone will be part of a successful launch of our Genomics Software Suite, helping us to work with more partners around the world and expanding the ever-growing value propositions of biomedical data analysis software solutions.”
December 2, 2020
OncoBone CSO Tiina Kähkönen has completed a medical writing certificate program and is now recognized as a Certified Medical Writing Professional (CMWP). The program was organized by the Center for Professional Innovation and Education (CfPIE). The courses in the program included technical writing for versioned and regulatory documents for pharmaceutical and biotech industry and medical devices.
September 23, 2020
OncoBone is proud to join Finnish Bioindustries (FIB) as a member company. By joining FIB OncoBone aims to network with Finnish life science companies and explore potential ways to promote Finnish excellence in life sciences to foreign markets.
September 1, 2020
OncoBone has launched new webpages to better visualize our concept and provide easier access to our services for our clients. With the new webpages we would like to welcome anyone interested in life science partnering to get in contact with us.
It has been a pleasure for OncoBone to work with Netello Systems in designing our new modern webpages. OncoBone would like to thank Netello for understanding the concept, excellent communication, and for the great execution of the work.
If you are interested to learn more,
see our services or contact us directly.